Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential.

Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has granted "breakthrough therapy designation" to psilocybin and MDMA for treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder, sparking global research efforts. Various clinical trials are currently investigating the therapeutic value of psilocybin for several mental health disorders. Results thus far indicate significant improvements in patient-reported outcomes via reductions in experiential avoidance. These advancements highlight a promising future for tryptamines in mental health therapy.